Search Results for:"Hemato Oncology"
FAQ: How are chimeric antigen receptors made?
Chimeric antigen receptors (CARs) are artificially engineered in a laboratory setting. To make CARs, scientists modify T-cells, a type of white blood cell, by introducing genetic material that encodes for the specific CAR protein. This genetic material is typically delivered to the T-cells using viral vectors, which act as carriers. Once inside the T-cells, the […]
FAQ: What to expect after CAR T-cell therapy?
After CAR T-cell therapy, patients can experience a range of responses. Some may achieve complete remission or significant disease reduction, leading to improved outcomes. However, there can also be side effects like cytokine release syndrome (CRS) or neurotoxicity, which require careful monitoring and management. Regular follow-up visits and assessments are essential to track treatment response […]
FAQ: What is CAR T-cell therapy for multiple myeloma?
CAR T-cell therapy has shown great promise in the treatment of multiple myeloma, a type of blood cancer affecting plasma cells. In this therapy, T-cells are extracted from the patient and genetically engineered to express chimeric antigen receptors (CARs) targeting the B-cell maturation antigen (BCMA), a protein commonly found on myeloma cells. After CAR modification, […]
FAQ: What does CAR stand for in CAR T-cell therapy?
CAR stands for Chimeric Antigen Receptor. In CAR T-cell therapy, T-cells are genetically modified in the laboratory to express CARs on their surface. These chimeric antigen receptors are designed to recognize specific antigens found on the surface of cancer cells. By introducing these receptors into the T-cells, they become equipped to target and attack cancer […]
FAQ: What cancers can be treated with CAR T-cell therapy?
CAR T-cell therapy has shown significant success in treating certain types of blood cancers. Currently, it is primarily approved and used to treat specific subtypes of leukemia and lymphoma. CAR T-cell therapy has been effective in treating acute lymphoblastic leukemia (ALL), certain cases of acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), […]
FAQ: Is CAR T-cell therapy immunotherapy?
Yes, CAR T-cell therapy is a form of immunotherapy. It utilizes the patient’s own immune system to fight cancer. T-cells, a type of white blood cell, are extracted from the patient and genetically engineered to express chimeric antigen receptors (CARs). These CARs enable the T-cells to recognize and target specific antigens present on cancer cells. […]
FAQ: How long does CAR T-cell therapy take?
The duration of CAR T-cell therapy can vary from patient to patient and depends on several factors, including the type of cancer being treated and the individual’s response to the treatment. Generally, the entire process can take a few weeks to complete. This includes the time required for leukapheresis to collect T-cells, the modification of […]
FAQ: How is CAR T-cell therapy done?
CAR T-cell therapy involves a multistep process that starts with the collection of the patient’s T-cells through leukapheresis. These T-cells are then modified in a laboratory to express chimeric antigen receptors (CARs) on their surface. The CARs are designed to recognize and target specific antigens present on cancer cells. After the CAR T-cells have been […]
FAQ: How is CAR T-cell therapy administered?
CAR T-cell therapy is administered in several steps. The process typically begins with leukapheresis, during which the patient’s blood is collected and T-cells are separated and isolated. These T-cells are then sent to a specialized laboratory, where they are genetically modified to express chimeric antigen receptors (CARs) specific to the patient’s cancer. Once the CAR […]
